Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioLineRx ADS Representing 15 Ord Shs BLRX

Healthcare Biotechnology
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform ,... see more

Recent & Breaking News (NDAQ:BLRX)

BioLineRx Reports Year End 2012 Financial Results

Business Wire March 12, 2013

BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main Therapeutic Pipeline as BL-9010

Business Wire February 28, 2013

BioLineRx to Report Fourth Quarter and Year End 2012 Results on March 12, 2013

Business Wire February 26, 2013

Free Research Reports on AGNC, BLRX, LDK and MCP Issued by the Bedford Report

Marketwired February 19, 2013

BioLineRx Announces Closing of $8 Million Offering of American Depositary Shares

Business Wire February 13, 2013

BioLineRx Announces Offering of American Depositary Shares

Business Wire February 6, 2013

BioLineRx Provides Clarification Regarding Interim Analysis of CLARITY Trial for BL-1020

Business Wire February 4, 2013

BioLineRx to Present at the 2013 BIO CEO & Investor Conference in New York on February 12th

Business Wire January 31, 2013

Free Research Reports on BLRX, DDD, NUE and PETM Issued by the Bedford Report

Marketwired January 29, 2013

The Real Story Behind NETE, BLRX, RSYS and GALT

Marketwired January 16, 2013

BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug During Week of March 18, 2013

Business Wire January 7, 2013